PCSK9 Inhibitors Show Value for Patients and the US Health Care System.

ABSTRACT:

Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors were approved by the US Food and Drug Administration (FDA) as cholesterol-lowering therapies for patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease.

Objectives

To estimate the long-term health and economic value of PCSK9 inhibitors for Americans (51 years and older).

Methods

We conducted simulations using the Future Elderly Model, an established dynamic microsimulation model to project the lifetime outcomes for the US population aged 51 years and older. Health effects estimates and confidence intervals from published meta-analysis studies were used to project changes in life expectancy, quality-adjusted life-years, and lifetime medical spending resulting from

SUBMITTER: Cheng WH 

PROVIDER: S-EPMC5929151 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature